然而，一位美国的专家警告此新研究发现 - 减少雌激素受体阴性（estrogen-receptor negative, ER-negative）乳癌风险的结果很可能纯属偶然。
基于1个网页-相关网页
Breast cancer can be broadly separated into hormone-responsive (ER-positive) and non-hormone-responsive (ER-negative) subtypes.
乳腺癌可以大致被分类为雌激素受体阳性与雌激素受体阴性两类。
In this model, higher clinical tumor stage and ER-negative status were associated with a statistically significantly greater risk for distant relapse or death.
在此模型中，更高的临床肿瘤分级及雌激素受体阴性与远处复发或死亡存在具有显著统计学差异的相关性。
These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
这些结果表明，AR可为预测ER阳性乳腺癌内分泌疗效的附加指标，以及ER阴性肿瘤靶向治疗的候选靶点。
应用推荐